Freestone Capital Holdings’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$16.6M Sell
65,869
-4,133
-6% -$889K 0.43% 37
2026
Q1
$15.2M Buy
70,002
+788
+1% +$175K 0.46% 33
2025
Q4
$15.8M Sell
69,214
-244
-0.4% -$55.6K 0.47% 38
2025
Q3
$16.1M Buy
69,458
+1,915
+3% +$390K 0.49% 36
2025
Q2
$12.5M Sell
67,543
-720
-1% -$134K 0.42% 40
2025
Q1
$14.3M Buy
68,263
+2,567
+4% +$499K 0.53% 33
2024
Q4
$11.7M Buy
65,696
+1,584
+2% +$291K 0.4% 47
2024
Q3
$12.7M Sell
64,112
-2,160
-3% -$403K 0.44% 46
2024
Q2
$11.4M Sell
66,272
-1,279
-2% -$212K 0.41% 48
2024
Q1
$12.3M Buy
67,551
+4,059
+6% +$700K 0.46% 43
2023
Q4
$9.84M Buy
63,492
+370
+0.6% +$53.9K 0.44% 46
2023
Q3
$9.41M Buy
63,122
+2,593
+4% +$381K 0.5% 46
2023
Q2
$8.16M Sell
60,529
-450
-0.7% -$66K 0.33% 58
2023
Q1
$9.72M Sell
60,979
-35
-0.1% -$5.35K 0.43% 43
2022
Q4
$9.86M Sell
61,014
-9,745
-14% -$1.49M 0.45% 38
2022
Q3
$9.5M Sell
70,759
-7,884
-10% -$1.13M 0.43% 35
2022
Q2
$12M Sell
78,643
-12,571
-14% -$1.92M 0.46% 31
2022
Q1
$14.8M Sell
91,214
-4,816
-5% -$700K 0.59% 32
2021
Q4
$13M Buy
96,030
+3,725
+4% +$440K 0.55% 40
2021
Q3
$9.96M Buy
92,305
+10,157
+12% +$1.16M 0.5% 45
2021
Q2
$9.25M Buy
82,148
+1,041
+1% +$117K 0.46% 49
2021
Q1
$8.78M Sell
81,107
-2,276
-3% -$243K 0.48% 51
2020
Q4
$8.93M Buy
83,383
+10,836
+15% +$1.04M 0.52% 39
2020
Q3
$6.35M Buy
72,547
+929
+1% +$87.5K 0.41% 55
2020
Q2
$7.03K Buy
71,618
+17,179
+32% +$1.51M 0.08% 53
2020
Q1
$4.15K Buy
54,439
+7,542
+16% +$642K 0.09% 81
2019
Q4
$4.15K Sell
46,897
-7,698
-14% -$639K 0.09% 97
2019
Q3
$4.13K Sell
54,595
-5,982
-10% -$410K 0.1% 97
2019
Q2
$4.41K Sell
60,577
-3,288
-5% -$258K 0.11% 111
2019
Q1
$5.15M Sell
63,865
-33,865
-35% -$2.77M 0.31% 97
2018
Q4
$9.01M Sell
97,730
-11,366
-10% -$1,000K 0.61% 42
2018
Q3
$10.3M Buy
109,096
+7,498
+7% +$711K 0.07% 51
2018
Q2
$9.41M Buy
101,598
+25,374
+33% +$2.48M 0.06% 58
2018
Q1
$7.21M Buy
76,224
+298
+0.4% +$32.7K 0.42% 64
2017
Q4
$7.34M Buy
75,926
+340
+0.4% +$32K 0.51% 54
2017
Q3
$6.72M Buy
75,586
+3,910
+5% +$298K 0.48% 57
2017
Q2
$5.2M Buy
71,676
+3,918
+6% +$263K 0.4% 57
2017
Q1
$4.42M Buy
67,758
+7,384
+12% +$464K 0.34% 58
2016
Q4
$3.78M Buy
60,374
+14,240
+31% +$869K 0.32% 66
2016
Q3
$2.91M Buy
46,134
+5,983
+15% +$387K 0.27% 77
2016
Q2
$2.49M Buy
40,151
+6,436
+19% +$392K 0.24% 78
2016
Q1
$1.93M Buy
33,715
+11,250
+50% +$627K 0.2% 89
2015
Q4
$1.33M Buy
22,465
+7,250
+48% +$418K 0.14% 120
2015
Q3
$828K Buy
15,215
+6,450
+74% +$420K 0.09% 178
2015
Q2
$589K Buy
8,765
+3,718
+74% +$243K 0.09% 158
2015
Q1
$295K Hold
5,047
0.05% 155
2014
Q4
$330K Hold
5,047
0.05% 150
2014
Q3
$292K Sell
5,047
-300
-6% -$16.7K 0.05% 123
2014
Q2
$302K Sell
5,347
-81
-1% -$4.25K 0.05% 161
2014
Q1
$279K Sell
5,428
-1,021
-16% -$51.6K 0.05% 163
2013
Q4
$341K Buy
6,449
+1,151
+22% +$56.6K 0.06% 226
2013
Q3
$237K Sell
5,298
-24,674
-82% -$1.09M 0.04% 301
2013
Q2
$1.24M Buy
+29,972
New +$1.31M 0.25% 58

Other funds holding ABBV

Freestone Capital Holdings's ABBV Position: Q2 2026 in Review

Freestone Capital Holdings reduced its AbbVie (ABBV) stake by 5.9% in Q2 2026, selling an estimated $889K and leaving 65,869 shares worth $16.6M. The position accounts for 0.43% of the portfolio, ranked #37.

Freestone Capital Holdings first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,190 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Freestone Capital Holdings held 65,869 shares of AbbVie worth $16.6M as of Q2 2026.
  • Freestone Capital Holdings sold 4,133 AbbVie shares in Q2 2026, an estimated $889K.
  • AbbVie made up 0.43% of Freestone Capital Holdings's portfolio in Q2 2026, its #37 holding.
  • Freestone Capital Holdings first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • 4,190 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Freestone Capital Holdings's 13F filing for Q2 2026, filed 31 Jul 2026.